Initial sequencing and analysis of the human genome

1. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis
of the human genome. Nature 2001;409:860–921.
2. Gosden RG, Feinberg AP. Genetics and epigenetics—nature’s pen-andpencil
set. N Engl J Med 2007;356:731–733.
3. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how
the genome integrates intrinsic and environmental signals. Nat Genet
2003;33(suppl):245–54.
4. Wang Z, Zang C, Rosenfeld JA, et al. Combinatorial patterns of histone
acetylations and methylations in the human genome. Nat Genet
2008;40:897–903.
5. Taverna SD, Li H, Ruthenburg AJ, et al. How chromatin-binding
modules interpret histone modifications: Lessons from professional
pocket pickers. Nat Struct Mol Biol 2007;14:1025–1040.
6. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators.
Trends Biochem Sci 2006;31:89–97.
7. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683–692.
8. Gal-Yam EN, Saito Y, Egger G, et al. Cancer epigenetics: modifications,
screening, and therapy. Annu Rev Med 2008;59:267–280.
9. Laird PW. Cancer epigenetics. Hum Mol Genet 2005;14 Spec No 1:
R65–R76.
10. Grønbaek K, Hother C, Jones PA. Epigenetic changes in cancer.
APMIS 2007;115:1039–1059.
11. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148–1159.
12. Bowman RV, Yang IA, Semmler AB, et al. Epigenetics of lung cancer.
Respirology 2006;11:355–365.
13. Risch A, Plass C. Lung cancer epigenetics and genetics. Int J Cancer
2008;123:1–7.
14. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung
cancer. Nat Rev Cancer 2004;4:707–717.
15. Tsou JA, Hagen JA, Carpenter CL, et al. DNA methylation
analysis: a powerful new tool for lung cancer diagnosis. Oncogene
2002;21:5450–5461.
16. Kerr KM, Galler JS, Hagen JA, et al. The role of DNA methylation in
the development and progression of lung adenocarcinoma. Dis Markers
2007;23:5–30.
17. Belinsky SA, Liechty KC, Gentry FD, et al. Promoter hypermethylation
of multiple genes in sputum precedes lung cancer incidence in a
high-risk cohort. Cancer Res 2006;66:3338–3344.
18. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation
markers and early recurrence in stage I lung cancer. N Engl J Med
2008;358:1118–1128.
19. Tsou JA, Galler JS, Siegmund KD, et al. Identification of a panel of
sensitive and specific DNA methylation markers for lung adenocarcinoma.
Mol Cancer 2007;6:70.
20. Anglim PA, Galler JS, Koss MN, et al. Identification of a panel of sensitive
and specific DNA methylation markers for squamous cell lung
cancer. Mol Cancer 2008;7:62.
21. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present, and
future. Nat Rev Drug Discov 2006;5:37–50.
22. Smith LT, Otterson GA, Plass C. Unraveling the epigenetic code of
cancer for therapy. Trends Genet 2007;23:449–456.
23. Wold B, Myers RM. Sequence census methods for functional genomics.
Nat Methods 2008;5:19–21.
24. Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer.
Annu Rev Med 2003;54:73–87.
25. Zochbauer-Muller S, Gazdar AF, Minna JD. Molecular pathogenesis of
lung cancer. Annu Rev Physiol 2002;64:681–708.
26. Brena RM, Costello JF. Genome-epigenome interactions in cancer.
Hum Mol Genet 2007;16 Spec No 1:R96–R105.
27. Miremadi A, Oestergaard MZ, Pharoah PD, et al. Cancer genetics of
epigenetic genes. Hum Mol Genet 2007;16 Spec No 1:R28–R49.
28. Patra SK. Ras regulation of DNA-methylation and cancer. Exp Cell Res
2008;314:1193–1201.
29. Povey AC, Margison GP, Santibáñez-Koref MF. Lung cancer risk
and variation in MGMT activity and sequence. DNA Repair (Amst)
2007;6:1134–1144.
30. Crosbie PA, McGown G, Thorncroft MR, et al. Association between
lung cancer risk and single nucleotide polymorphisms in the first
intron and codon 178 of the DNA repair gene, o6-alkylguanine-DNA
alkyltransferase. Int J Cancer 2008;122:791–795.
31. Zienolddiny S, Campa D, Lind H, et al. Polymorphisms of DNA
repair genes and risk of non-small cell lung cancer. Carcinogenesis
2006;27:560–567.
32. Chen T, Li E. Establishment and maintenance of DNA methylation
patterns in mammals. Curr Top Microbiol Immunol 2006;301:179–201.
33. Chen T, Li E. Structure and function of eukaryotic DNA methyltransferases.
Curr Top Dev Biol 2004;60:55–89.
34. Linhart HG, Lin H, Yamada Y, et al. DNMT3B promotes tumorigenesis
in vivo by gene-specific de novo methylation and transcriptional
silencing. Genes Dev 2007;21:3110–3122.
35. Wang J, Bhutani M, Pathak AK, et al. Delta DNMT3B variants regulate
DNA methylation in a promoter-specific manner. Cancer Res
2007;67:10647–10652.
36. Pfeifer GP. Mutagenesis at methylated CpG sequences. Curr Top
Microbiol Immunol 2006;301:259–281.
37. Takai D, Jones PA. Comprehensive analysis of CpG islands in
the human chromosomes 21 and 22. Proc Natl Acad Sci USA
2002;99:3740–3745.
38. Anglim PP, Alonzo TT, Laird-Offringa IA. DNA methylation-based
biomarkers for early detection of non-small cell lung cancer: An update.
Mol Cancer 2008;23:81.
39. Laird PW. The power and the promise of DNA methylation markers.
Nat Rev Cancer 2003;3:253–266.
40. Olek A, Oswald J, Walter J. A modified and improved method for
bisulphite based cytosine methylation analysis. Nucleic Acids Res
1996;24:5064–5066.
41. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing
protocol that yields a positive display of 5-methylcytosine residues in individual
DNA strands. Proc Natl Acad Sci USA 1992;89:1827–1831.
42. Herman JG, Graff JR, Myöhänen S, Nelkin BD, et al. Methylationspecific
pcr: a novel pcr assay for methylation status of CpG islands.
Proc Natl Acad Sci USA 1996;93:9821–9826.
43. Trinh BN, Long TI, Laird PW. DNA methylation analysis by
MethyLight technology. Methods 2001;25:456–462.
44. Eads CA, Danenberg KD, Kawakami K, et al. Methylight: a high-throughput
assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
45. Costello JC, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island
methylation has non-random and tumor-type-specific patterns. Nature
Genet 2000;25:132–138.
46. Huang TH, Perry MR, Laux DE. Methylation profiling of CpG islands
in human breast cancer cells. Hum Mol Genet 1999;8:459–470.
47. Rauch T, Li H, Wu X, et al. Mira-assisted microarray analysis, a new
technology for the determination of DNA methylation patterns, identifies
frequent methylation of homeodomain-containing genes in lung
cancer cells. Cancer Res 2006;66:7939–7947.
48. Weber M, Davies JJ, Wittig D, et al. Chromosome-wide and promoter-
specific analyses identify sites of differential DNA methylation
in normal and transformed human cells. Nat Genet 2005;37:853–862.
49. Shames DS, Girard L, Gao B, et al. A genome-wide screen for promoter
methylation in lung cancer identifies novel methylation markers
for multiple malignancies. PLoS Med 2006;3:E486.
50. Meissner A, Mikkelsen TS, Gu H, et al. Genome-scale DNA methylation
maps of pluripotent and differentiated cells. Nature 2008;454:766–770.
51. Bibikova M, Lin Z, Zhou L, et al. High-throughput DNA methylation
profiling using universal bead arrays. Genome Res 2006;16:383–393.
52. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some
human cancers from their normal counterparts. Nature 1983;301:89–92.
53. Kohda M, Hoshiya H, Katoh M, et al. Frequent loss of imprinting of IGF2
and MEST in lung adenocarcinoma. Mol Carcinog 2001;31:184–191.
54. Kondo M, Suzuki H, Ueda R, et al. Frequent loss of imprinting of the
H19 gene is often associated with its overexpression in human lung
cancers. Oncogene 1995;10:1193–1198.
55. Simpson AJ, Caballero OL, Jungbluth A, et al. Cancer/testis antigens,
gametogenesis and cancer. Nat Rev Cancer 2005;5:615–625.
56. Scanlan MJ, Altorki NK, Gure AO, et al. Expression of cancer-testis
antigens in lung cancer: definition of bromodomain testis-specific gene
(BRDT) as a new CT gene, CT9. Cancer Lett 2000;150:155–164.
57. Jang SJ, Soria JC, Wang L, et al. Activation of melanoma antigen
tumor antigens occurs early in lung carcinogenesis. Cancer Res
2001;61:7959–7963.
58. Rauch TA, Zhong X, Wu X, et al. High-resolution mapping of DNA
hypermethylation and hypomethylation in lung cancer. Proc Natl Acad
Sci USA 2008;105:252–257.
59. Cowland JB, Hother C, Grønbaek K. Micrornas and cancer. APMIS
2007;115:1090–1106.
60. Saito Y, Jones PA. Epigenetic activation of tumor suppressor microRNAs
in human cancer cells. Cell Cycle 2006;5:2220–2222.
61. Brueckner B, Stresemann C, Kuner R, et al. The human let-7a-3 locus
contains an epigenetically regulated microRNA gene with oncogenic
function. Cancer Res 2007;67:1419–1423.
62. Eden A, Gaudet F, Waghmare A, et al. Chromosomal instability and
tumors promoted by DNA hypomethylation. Science 2003;300:455.
63. Karpf AR, Matsui S. Genetic disruption of cytosine DNA methyltransferase
enzymes induces chromosomal instability in human cancer cells.
Cancer Res 2005;65:8635–8639.
64. Trinh BN, Long TI, Nickel AE, et al. DNA methyltransferase deficiency
modifies cancer susceptibility in mice lacking DNA mismatch
repair. Mol Cell Biol 2002;22:2906–2917.
65. Cantor JP, Iliopoulos D, Rao AS, et al. Epigenetic modulation of
endogenous tumor suppressor expression in lung cancer xenografts
suppresses tumorigenicity. Int J Cancer 2007;120:24–31.
66. Belinsky SA, Klinge DM, Stidley CA, et al. Inhibition of DNA methylation
and histone deacetylation prevents murine lung cancer. Cancer
Res 2003;63:7089–7093.
67. Clouaire T, Stancheva I. Methyl-CpG binding proteins: specialized
transcriptional repressors or structural components of chromatin? Cell
Mol Life Sci 2008;65:1509–1522.
68. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development
for early detection of cancer. J Natl Cancer Inst 2001;93:1054–1061.
69. Travis WD. Pathology of lung cancer. Clin Chest Med 2002;23:65–81.
70. Bach PB. Is our natural-history model of lung cancer wrong? Lancet
Oncol 2008;9:693–697.
71. Virmani AK, Tsou JA, Siegmund KD, et al. Hierarchical clustering of
lung cancer cell lines using DNA methylation markers. Cancer Epid
Biom Prev 2002;11:291–297.
72. Toyooka S, Toyooka KO, Maruyama R, et al. DNA methylation profiles
of lung tumors. Mol Cancer Therap 2001;1:61–67.
73. Sathyanarayana UG, Toyooka S, Padar A, et al. Epigenetic inactivation
of laminin-5-encoding genes in lung cancers. Clin Cancer Res
2003;9:2665–2672.
74. Tsou JA, Galler JS, Siegmund KD, et al. Identification of a panel
of highly sensitive and specific DNA methylation markers for lung
adenocarcinoma. Mol Cancer 2007;6:70.
75. Ehrich M, Field JK, Liloglou T, et al. Cytosine methylation profiles
as a molecular marker in non-small cell lung cancer. Cancer Res
2006;66:10911–10918.
76. Brena RM, Morrison C, Liyanarachchi S, et al. Aberrant DNA methylation
of OLIG1, a novel prognostic factor in non-small cell lung
cancer. PLoS Med 2007;4:E108.
77. Toyooka S, Maruyama R, Toyooka KO, et al. Smoke exposure, histologic
type and geography-related differences in the methylation profiles
of non-small cell lung cancer. Int J Cancer 2003;103:153–160.
78. Hofmann HS, Bartling B, Simm A, et al. Identification and classification
of differentially expressed genes in non-small cell lung cancer
by expression profiling on a global human 59.620-element oligonucleotide
array. Oncol Rep 2006;16:587–595.
79. Zhou W, Heist RS, Liu G, et al. Polymorphisms of vitamin D receptor
and survival in early-stage non-small cell lung cancer patients. Cancer
Epidemiol Biomarkers Prev 2006;15:2239–2245.
80. Raponi M, Zhang Y, Yu J, et al. Gene expression signatures for predicting
prognosis of squamous cell and adenocarcinomas of the lung.
Cancer Res 2006;66:7466–7472.
81. Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor
receptor and KRAS mutation patterns in non-small cell lung cancer
patients with different tobacco exposure and clinicopathologic features.
Clin Cancer Res 2006;12:1647–1653.
82. Vineis P, Husgafvel-Pursiainen K. Air pollution and cancer: biomarker
studies in human populations. Carcinogenesis 2005;26:1846–1855.
83. Issa JP. CpG-island methylation in aging and cancer. Curr Top Microbiol
Immunol 2000;249:101–118.
84. Belinsky SA, Snow SS, Nikula KJ, et al. Aberrant CpG island
methylation of the p16(ink4a) and estrogen receptor genes in rat
lung tumors induced by particulate carcinogens. Carcinogenesis
2002;23:335–339.
85. Marsit CJ, Kim DH, Liu M, et al. Hypermethylation of RASSF1A
and BLU tumor suppressor genes in non-small cell lung cancer: implications
for tobacco smoking during adolescence. Int J Cancer
2005;114:219–223.
86. Dai Z, Lakshmanan RR, Zhu WG, et al. Global methylation profiling of
lung cancer identifies novel methylated genes. Neoplasia 2001;3:314–323.
87. Cortese R, Hartmann O, Berlin K, et al. Correlative gene expression
and DNA methylation profiling in lung development nominate new
biomarkers in lung cancer. Int J Biochem Cell Biol 2008;40:1494–1508.
88. Feng Q, Hawes SE, Stern JE, et al. DNA methylation in tumor and
matched normal tissues from non-small cell lung cancer patients.
Cancer Epidemiol Biomarkers Prev 2008;17:645–654.
89. Field JK, Liloglou T, Warrak S, et al. Methylation discriminators
in NSCLC identified by a microarray based approach. Int J Oncol
2005;27:105–111.
90. Fukasawa M, Kimura M, Morita S, et al. Microarray analysis of promoter
methylation in lung cancers. J Hum Genet 2006;51:368–374.
91. Hatada I, Fukasawa M, Kimura M, et al. Genome-wide profiling of
promoter methylation in human. Oncogene 2006;25:3059–3064.
92. Rauch T, Wang Z, Zhang X, et al. Homeobox gene methylation in
lung cancer studied by genome-wide analysis with a microarray-based
methylated CpG island recovery assay. Proc Natl Acad Sci U S A
2007;104:5527–5532.
93. Widschwendter M, Fiegl H, Egle D, et al. Epigenetic stem cell signature
in cancer. Nat Genet 2007;39:157–158.
94. Carpagnano GE, Foschino-Barbaro MP, Spanevello A, et al. 3p microsatellite
signature in exhaled breath condensate and tumor tissue of patients
with lung cancer. Am J Respir Crit Care Med 2008;177:337–341.
95. Gessner C, Kuhn H, Toepfer K, et al. Detection of p53 gene mutations
in exhaled breath condensate of non-small cell lung cancer patients.
Lung Cancer 2004;43:215–222.
96. Powell CA. Waiting to exhale. Am J Respir Crit Care Med 2008;177:
246–247.
97. Schmiemann V, Bocking A, Kazimirek M, et al. Methylation assay for
the diagnosis of lung cancer on bronchial aspirates: A cohort study.
Clin Cancer Res 2005;11:7728–7734.
98. Grote HJ, Schmiemann V, Geddert H, et al. Aberrant promoter methylation
of p16(ink4a), RARB2 and SEMA3B in bronchial aspirates from
patients with suspected lung cancer. Int J Cancer 2005;116:720–725.
99. Topaloglu O, Hoque MO, Tokumaru Y, et al. Detection of promoter
hypermethylation of multiple genes in the tumor and bronchoalveolar lavage
of patients with lung cancer. Clin Cancer Res 2004;10:2284–2288.
100. Zöchbauer-Müller S, Fong KM, et al. Aberrant promoter methylation
of multiple genes in non-small cell lung cancers. Cancer Res
2001;61:249–255.
101. Kersting M, Friedl C, Kraus A, et al. Differential frequencies of
p16ink4a promoter hypermethylation, p53 mutation, and K-ras mutation
in exfoliative material mark the development of lung cancer in
symptomatic chronic smokers. J Clin Oncol 2000;18:3221–3229.
102. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of
p16 ink4a is an early event in lung cancer and potential biomarker for
early diagnosis. Proc Natl Acad Sci USA 1998;95:11891–11896.
103. Palmisano WA, Crume KP, Grimes MJ, et al. Aberrant promoter methylation
of the transcription factor genes PAX5 alpha and beta in human
cancers. Cancer Res 2003;63:4620–4625.
104. Gordon GJ, Jensen RV, Hsiao LL, et al. Using gene expression ratios to
predict outcome among patients with mesothelioma. J Natl Cancer Inst
2003;95:598–605.
105. Belinsky SA. Role of the cytosine DNA-methyltransferase and p16/
ink4a genes in the development of mouse lung tumors. Exp Lung Res
1998;24:463–479.
106. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A
practical and powerful approach to multiple testing. J R Statist Soc B
1995;57:289–300.
107. Tanaka H, Fujii Y, Hirabayashi H, et al. Disruption of the RB pathway
and cell-proliferative activity in non-small cell lung cancers. Int J
Cancer 1998;79:111–115.
108. Kashiwabara K, Oyama T, Sano T, et al. Correlation between the methylation
status of the p16/CDKN2A gene and the expression of the p16
and RB proteins in primary non-small cell lung cancer. Int J Cancer
1998;79:215–220.
109. Licchesi JD, Westra WH, Hooker CM, et al. Promoter hypermethylation
of hallmark cancer genes in atypical adenomatous hyperplasia of
the lung. Clin Cancer Res 2008;14:2570–2578.
110. Ramirez RD, Sheridan S, Girard L, et al. Immortalization of human
bronchial epithelial cells in the absence of viral oncoproteins. Cancer
Res 2004;64:9027–9034.
111. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M. Stem cells and
cancer; the polycomb connection. Cell 2004;118:409–418.
112. Toyooka S, Suzuki M, Maruyama R, et al. The relationship between
aberrant methylation and survival in non-small cell lung cancers. Br J
Cancer Res 2004;91:771–774.
113. Pulling LC, Divine KK, Klinge DM, et al. Promoter hypermethylation
of the o6-methylguanine-DNA methyltransferase gene: more common
in lung adenocarcinomas from never-smokers than smokers and associated
with tumor progression. Cancer Res 2003;63:4842–4848.
114. Brabender J, Usadel H, Metzger R, et al. Quantitative o(6)-methylguanine
DNA methyltransferase methylation analysis in curatively resected
non-small cell lung cancer: associations with clinical outcome.
Clin Cancer Res 2003;9:223–227.
115. Liu Y, Lan Q, Siegfried JM, et al. Aberrant promoter methylation of p16
and MGMT genes in lung tumors from smoking and never-smoking
lung cancer patients. Neoplasia 2006;8:46–51.
116. Bogos K, Renyi-Vamos F, Kovacs G, et al. Role of retinoic receptors in
lung carcinogenesis. J Exp Clin Cancer Res 2008;27:18.
117. Omenn GS. Chemoprevention of lung cancers: lessons from CARET,
the beta-carotene and retinol efficacy trial, and prospects for the future.
Eur J Cancer Prev 2007;16:184–191.
118. Langenfeld J, Lonardo F, Kiyokawa H, et al. Inhibited transformation
of immortalized human bronchial epithelial cells by retinoic acid is
linked to cyclin E down-regulation. Oncogene 1996;13:1983–1990.
119. Petty WJ, Li N, Biddle A, et al. A novel retinoic acid receptor beta
isoform and retinoid resistance in lung carcinogenesis. J Natl Cancer
Inst 2005;97:1645–1651.
120. Licchesi JD, Westra WH, Hooker CM, et al. Epigenetic alteration
of Wnt pathway antagonists in progressive glandular neoplasia of the
lung. Carcinogenesis 2008;29:895–904.
121. Pfeifer GP, Dammann R. Methylation of the tumor suppressor gene
RASSF1A in human tumors. Biochemistry (Mosc) 2005;70:576–583.
122. Yanagawa N, Tamura G, Oizumi H, et al. Promoter hypermethylation
of RASSF1A and RUX3 genes as an independent prognostic prediction
marker in surgically resected non-small cell lung cancers. Lung Cancer
2007;58:131–138.
123. Maneckjee R, Minna JD. Opioids induce while nicotine suppresses apoptosis
in human lung cancer cells. Cell Growth Differ 1994;5:1033–1040.
124. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts
aberrant methylation in lung cancer by targeting DNA methyltransferases
3A and 3B. Proc Natl Acad Sci U S A 2007;104:15805–15810.
125. Bhaumik SR, Smith E, Shilatifard A. Covalent modifications of histones
during development and disease pathogenesis. Nat Struct Mol
Biol 2007;14:1008–1016.
126. Adcock IM, Ford P, Ito K, et al. Epigenetics and airways disease. Respir
Res 2006;7:21.
127. Barlési F, Giaccone G, Gallegos-Ruiz MI, et al. Global histone modifications
predict prognosis of resected non small-cell lung cancer. J Clin
Oncol 2007;25:4358–4364.
128. Schrump DS, Hong JA, Nguyen DM. Utilization of chromatin remodeling
agents for lung cancer therapy. Cancer J 2007;13:56–64.
129. Aparicio A. The potential of histone deacetylase inhibitors in lung
cancer. Clin Lung Cancer 2006;7:309–312.
130. Gridelli C, Rossi A, Maione P. The potential role of histone deacetylase
inhibitors in the treatment of non-small-cell lung cancer. Crit Rev
Oncol Hematol 2008;68:29–36.
131. Edwards A, Li J, Atadja P, et al. Effect of the histone deacetylase inhibitor
LBH589 against epidermal growth factor receptor-dependent
human lung cancer cells. Mol Cancer Ther 2007;6:2515–2524.
132. Kamemura K, Ito A, Shimazu T, et al. Effects of downregulated
HDAC6 expression on the proliferation of lung cancer cells. Biochem
Biophys Res Commun 2008; 74:84–89.
133. Shimamura T, Shapiro GI. Heat shock protein 90 inhibition in lung
cancer. J Thorac Oncol 2008;3:S152–S159.
134. Yu XD, Wang SY, Chen GA, et al. Apoptosis induced by depsipeptide
FK228 coincides with inhibition of survival signaling in lung cancer
cells. Cancer J 2007;13:105–113.
135. Chen G, Li A, Zhao M, et al. Proteomic analysis identifies protein targets
responsible for depsipeptide sensitivity in tumor cells. J Proteome
Res 2008;7:2733–2742.
136. Geng L, Cuneo KC, Fu A, et al. Histone deacetylase (HDAC) inhibitor
LBH589 increases duration of gamma-H2AX foci and confines
HDAC4 to the cytoplasm in irradiated non-small cell lung cancer.
Cancer Res 2006;66:11298–11304.
137. Chai G, Li L, Zhou W, et al. HDAC inhibitors act with 5-aza-2 -deoxycytidine
to inhibit cell proliferation by suppressing removal of incorporated
abases in lung cancer cells. PLoS ONE 2008;3:e2445.
138. Shivapurkar N, Stastny V, Suzuki M, et al. Application of a methylation
gene panel by quantitative pcr for lung cancers. Cancer Lett
2007;247:56–71.
139. Grote HJ, Schmiemann V, Kiel S, et al. Aberrant methylation of the
adenomatous polyposis coli promoter 1A in bronchial aspirates from
patients with suspected lung cancer. Int J Cancer 2004;110:751–755.
140. de Fraipont F, Moro-Sibilot D, Michelland S, et al. Promoter methylation
of genes in bronchial lavages: a marker for early diagnosis of primary and
relapsing non-small cell lung cancer? Lung Cancer 2005;50:199–209.
141. Usadel H, Brabender J, Danenberg KD, et al. Quantitative adenomatous
polyposis coli promoter methylation analysis in tumor tissue,
serum, and plasma DNA of patients with lung cancer. Cancer Res
2002;62:371–375.
142. Belinsky SA, Klinge DM, Dekker JD, et al. Gene promoter methylation
in plasma and sputum increases with lung cancer risk. Clin Cancer
Res 2005;11:6505–6511.
143. Belinsky SA, Grimes MJ, Casas E, et al. Predicting gene promoter
methylation in non-small-cell lung cancer by evaluating sputum and
serum. Br J Cancer 2007;96:1278–1283.
144. Kim H, Kwon YM, Kim JS, et al. Tumor-specific methylation in bronchial
lavage for the early detection of non-small-cell lung cancer. J Clin
Oncol 2004;22:2363–2370.
145. Ulivi P, Zoli W, Calistri D, et al. p16INK4A and CDH13 hypermethylation
in tumor and serum of non-small cell lung cancer patients.
J Cell Physiol 2006;206:611–615.
146. Hsu HS, Chen TP, Hung CH, et al. Characterization of a multiple
epigenetic marker panel for lung cancer detection and risk assessment
in plasma. Cancer 2007;110:2019–2026.
147. Cirincione R, Lintas C, Conte D, et al. Methylation profile in
tumor and sputum samples of lung cancer patients detected by spiral
computed tomography: a nested case-control study. Int J Cancer
2006;118:1248–1253.
148. Liu Y, An Q, Li L, et al. Hypermethylation of p16INK4A in Chinese
lung cancer patients: Biological and clinical implications. Carcinogenesis
2003;24:1897–1901.
149. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer
by detecting aberrant promoter methylation in sputum. Cancer Res
2000;60:5954–5958.
150. Olaussen KA, Soria JC, Park YW, et al. Assessing abnormal gene promoter
methylation in paraffin-embedded sputum from patients with
NSCLC. Eur J Cancer 2005;41:2112–2119.
151. Chan EC, Lam SY, Tsang KW, et al. Aberrant promoter methylation in
Chinese patients with non-small cell lung cancer: Patterns in primary
tumors and potential diagnostic application in bronchoalevolar lavage.
Clin Cancer Res 2002;8:3741–3746.
152. Kurakawa E, Shimamoto T, Utsumi K, et al. Hypermethylation of
p16(INK4A) and p15(INK4B) genes in non-small cell lung cancer. Int
J Oncol 2001;19:277–281.
153. Ahrendt SA, Chow JT, Xu LH, et al. Molecular detection of tumor
cells in bronchoalveolar lavage fluid from patients with early stage lung
cancer. J Natl Cancer Inst 1999;91:332–339.
154. Guo M, House MG, Hooker C, et al. Promoter hypermethylation of
resected bronchial margins: a field defect of changes? Clin Cancer Res
2004;10:5131–5136.
155. Ng CSH, Zhang J, Wan S, et al. Tumor p16M is a possible marker of
advanced stage in non-small cell lung cancer. J Surg Oncol 2002;79:
101–106.
156. Fujiwara K, Fujimoto N, Tabata M, et al. Identification of epigenetic
aberrant promoter methylation in serum DNA is useful for early detection
of lung cancer. Clin Cancer Res 2005;11:1219–1225.
157. Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant
promoter hypermethylation of tumor suppressor genes in serum DNA
from non-small cell lung cancer patients. Cancer Res 1999;59:67–70.
158. Bearzatto A, Conte D, Frattini M, et al. P16(INK4A) hypermethylation
detected by fluorescent methylation-specific PCR in plasmas
from non-small cell lung cancer. Clin Cancer Res 2002;8:3782–3787.
159. Wang YC, Lu YP, Tseng RC, et al. Inactivation of HMLH1 and
HMSH2 by promoter methylation in primary non-small cell lung tumors
and matched sputum samples. J Clin Invest 2003;111:887–895.
160. Grote HJ, Schmiemann V, Geddert H, et al. Methylation of Ras association
domain family protein 1A as a biomarker of lung cancer. Cancer
2006;108:129–134.
161. Sozzi G, Musso K, Ratcliffe C, et al. Detection of microsatellite alterations
in plasma DNA of non-small cell lung cancer patients: a prospect
for early diagnosis. Clin Cancer Res 1999;5:2689–2692.
162. Wang Y, Yu Z, Wang T, et al. Identification of epigenetic aberrant promoter
methylation of RASSF1A in serum DNA and its clinicopathological
significance in lung cancer. Lung Cancer 2007;56:289–294.
163. Shivapurkar N, Stastny V, Xie Y, et al. Differential methylation of a short
CpG-rich sequence within exon 1 of TCF21 gene: a promising cancer
biomarker assay. Cancer Epidemiol Biomarkers Prev 2008;17:995–1000.